The United Nations Development Programme (UNDP) has announced plans to address the members of Parliament, and parliamentary ...

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

Patients receiving Monjuvi in combination with rituximab and lenalidomide achieved a median PFS by investigator assessment of 22.4 months (95% CI, 19.2-not evaluable [NE]) compared to 13.9 months ...

An unexpected relapse has columnist Ahna Crum contemplating what remains when the miracle of stem cell transplant seems ...

The world must have heaved a huge sigh of relief on hearing that Israel and Iran had agreed to a ceasefire. An uneasy truce between two belligerent nations, after nearly two weeks of intense fighting, ...

More than 50 insurers have pledged to streamline and simplify the prior authorization process through six new commitments.